Barrington Research Issues Positive Forecast for Haemonetics (NYSE:HAE) Stock Price

Haemonetics (NYSE:HAE) had its price target upped by Barrington Research from $86.00 to $90.00 in a report published on Friday,Benzinga reports. The firm currently has an outperform rating on the medical instruments supplier’s stock. Barrington Research also issued estimates for Haemonetics’ Q3 2026 earnings at $1.27 EPS, Q4 2026 earnings at $1.29 EPS, FY2026 earnings at $4.93 EPS, Q1 2027 earnings at $1.21 EPS, Q2 2027 earnings at $1.43 EPS, Q3 2027 earnings at $1.40 EPS, Q4 2027 earnings at $1.42 EPS, FY2027 earnings at $5.45 EPS and FY2028 earnings at $6.00 EPS.

Several other equities analysts have also recently weighed in on the company. Citigroup cut their price objective on Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a research report on Tuesday, October 7th. Raymond James Financial cut Haemonetics from a “strong-buy” rating to an “outperform” rating and reduced their price objective for the company from $105.00 to $78.00 in a research report on Monday, August 11th. BTIG Research raised their price objective on shares of Haemonetics from $85.00 to $88.00 and gave the stock a “buy” rating in a research note on Thursday. Needham & Company LLC upped their target price on shares of Haemonetics from $68.00 to $78.00 and gave the company a “buy” rating in a research note on Friday. Finally, Weiss Ratings downgraded shares of Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Saturday, October 25th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Haemonetics presently has an average rating of “Moderate Buy” and a consensus target price of $78.50.

Haemonetics Stock Performance

HAE traded up $1.59 on Friday, hitting $68.70. The company had a trading volume of 3,209,056 shares, compared to its average volume of 849,000. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.72 and a quick ratio of 1.04. The company’s fifty day moving average price is $51.53 and its 200 day moving average price is $62.10. The stock has a market cap of $3.31 billion, a price-to-earnings ratio of 21.01, a price-to-earnings-growth ratio of 0.91 and a beta of 0.43. Haemonetics has a 1-year low of $47.31 and a 1-year high of $94.99.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, topping the consensus estimate of $1.12 by $0.15. The firm had revenue of $327.32 million for the quarter, compared to the consensus estimate of $311.61 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The business’s quarterly revenue was down 5.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.12 EPS. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Equities analysts predict that Haemonetics will post 4.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in HAE. Norges Bank acquired a new stake in Haemonetics during the second quarter valued at approximately $36,822,000. SG Capital Management LLC boosted its stake in Haemonetics by 92.5% in the 2nd quarter. SG Capital Management LLC now owns 906,892 shares of the medical instruments supplier’s stock valued at $67,663,000 after buying an additional 435,660 shares in the last quarter. Citigroup Inc. boosted its stake in Haemonetics by 87.3% in the 1st quarter. Citigroup Inc. now owns 625,565 shares of the medical instruments supplier’s stock valued at $39,755,000 after buying an additional 291,574 shares in the last quarter. AQR Capital Management LLC grew its position in Haemonetics by 157.9% in the second quarter. AQR Capital Management LLC now owns 450,248 shares of the medical instruments supplier’s stock valued at $33,390,000 after acquiring an additional 275,683 shares during the period. Finally, River Road Asset Management LLC raised its stake in Haemonetics by 18.7% during the second quarter. River Road Asset Management LLC now owns 1,655,676 shares of the medical instruments supplier’s stock worth $122,586,000 after acquiring an additional 260,624 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.